Zenas BioPharma's (ZBIO) obexelimab met all primary and secondary endpoints with "statistically significant" results in a phase 3 study in patients with immunoglobulin G4-related disease, the company said Tuesday.
Obexelimab "significantly" lowered disease activity and flare-ups as well as glucocorticoid use compared with placebo in the 52-week study, the company said.
The drug's safety profile was also comparable to placebo, the company said.
Immunoglobulin G4-related disease is an autoimmune disorder.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments